Testing solutions to streamline laboratory practices and support better patient care
Diagnostics to detect infection and genetic markers for antibiotic resistance support Resistance Guided Therapy, a crucial patient care strategy when treating sexually transmitted infections (STIs) in the face of rising antimicrobial resistance (AMR).
Prof. Vincent Cattoir
![](https://plexpcr.com/wp-content/uploads/2019/08/Vincent-Cattoir_v2.jpg)
Assessing the SpeeDx total STI testing solution – how laboratory workflow can enable Resistance Guided Therapy
The Director of Department of Bacteriology in Hospital Hygiene Rennes Hospital Prof. Cattoir shares:
- His view on the need for new, rapid molecular tools to guide therapy and limit AMR spread
- Preview of a multiplex screening assay (beta) for detection of CT, NG, MG and TV, followed by relevant reflex test cascade for positive samples:
- Mycoplasma genitalium – ResistancePlus MG for macrolide resistance screening, and MG + ParC (beta) for fluoroquinolone resistance
- Gonorrhoea – ResistancePlus GC for ciprofloxacin susceptibility
- Chlamydia – Lymphogranuloma venereum LGV (beta)
Dr. Emily Goldstein
![Syphilis-slide](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)
Comprehensive lesion testing and the importance of molecular syphilis result
A Senior Biomedical Scientist in West of Scotland Specialist Virology Centre (Glasgow Royal Infirmary), Dr. Goldstein discusses:
- The increasing rates of syphilis disease and importance of early diagnosis and routine screening of all lesions with molecular testing
- Detection of several syphilis positive patients that would not have been selected for serology syphilis screening, thus may have gone undetected
- The results of her evaluation of the multiplex test PlexPCR VHS to detect and differentiate Herpes type 1 & 2, varicella zoster, and T. pallidum
Resistance Guided Therapy
Diagnostics that detect infection and genetic markers for antibiotic resistance support Resistance Guided Therapy, a crucial patient care strategy when treating sexually transmitted infections (STIs) in the face of rising antimicrobial resistance (AMR).
Dr. Jørgen Skov Jensen
![Jorgen-Jensen-ECCMID](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)
Molecular tests for M. genitalium resistance to 1st and 2nd -line therapy
A recognised leader in Mycoplasma genitalium (Mgen) research and diagnostics, Dr. Jensen shares data and insights on:
- ResistancePlus MG FleXible for the GeneXpert – bringing Resistance Guided Therapy closer to the patient, evaluating Mgen resistance cartridge-based detection.
- Testing for resistance to 2nd -line antibiotics using the SpeeDx MG + ParC (beta) test
Dr. Kate Templeton
![Kate-Templeton-Profile](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)
Practical implementation of ResistancePlus GC -incorporating ciprofloxacin susceptibility with gonorrhoea results
Director of SBSTRIL, national STI reference laboratory in Scotland, Dr. Templeton spotlights gonorrhoea and discusses:
- Practical implementation of Resistance Guided Therapy for gonorrhoea
- Potential to disrupt empiric treatment practices and adhere to new BASHH guidelines for preferential use of ciprofloxacin